Volume | 79,856 |
|
|||||
News | - | ||||||
Day High | 6.935 | Low High |
|||||
Day Low | 6.60 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Capricor Therapeutics Inc | CAPR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
6.74 | 6.60 | 6.935 | 6.77 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
789 | 79,856 | $ 6.76 | $ 540,039 | - | 2.68 - 8.2212 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
12:12:54 | 5 | $ 6.86 | USD |
Capricor Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
215.4M | 31.40M | - | 2.55M | -29.02M | -0.92 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Capricor Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CAPR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 6.92 | 7.04 | 5.80 | 6.57 | 464,829 | -0.06 | -0.87% |
1 Month | 4.43 | 7.22 | 4.10 | 6.09 | 423,236 | 2.43 | 54.85% |
3 Months | 5.13 | 7.22 | 3.56 | 5.25 | 278,710 | 1.73 | 33.72% |
6 Months | 5.91 | 7.22 | 2.68 | 4.24 | 289,235 | 0.95 | 16.07% |
1 Year | 4.10 | 8.2212 | 2.68 | 4.58 | 193,747 | 2.76 | 67.32% |
3 Years | 5.02 | 8.2212 | 2.56 | 4.52 | 262,270 | 1.84 | 36.65% |
5 Years | 0.5766 | 12.32 | 0.2526 | 5.89 | 756,546 | 6.28 | 1,089.73% |
Capricor Therapeutics Description
Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy (DMD). Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor's proprietary StealthX¿ exosome platform has potential for a broad range of new therapeutic applications in the field of vaccinology as well as targeted oligonucleotide, protein and small molecule therapeutics to treat or prevent a variety of diseases. |